Scientific deep-dive
The Group That Lost Least Did Best
A study compared surgery, semaglutide and a lifestyle program in young women with endometrial cancer. The group that lost the least weight had the highest tumor remission rate, and that is almost certainly not what it looks like.
In young women with endometrial cancer who want to preserve fertility, losing weight is part of the cancer treatment rather than a side project. A study compared three routes (surgery, semaglutide, and an intensive lifestyle program) and found the group that lost the least weight had the highest rate of complete tumor remission.[1] That is almost certainly not what it looks like, and the reasons are instructive.
Why weight matters in this cancer
Endometrial cancer is strongly linked to excess weight, through estrogen produced in fat tissue. In younger women who want to keep the option of pregnancy, standard surgery removes that option, so fertility-sparing treatment uses hormonal therapy and aims to reverse the conditions that produced the cancer. Weight loss is part of the oncological plan.
| Sleeve gastrectomy | Semaglutide | Lifestyle program | |
|---|---|---|---|
| Number | 10 | 23 | 20 |
| BMI reduction at 1 year | Largest | 4.04 kg/m² less than surgery | 2.12 kg/m² less than surgery |
| Weight regain by 2 years | 66.7% | 55.6% | 14.3% |
| Complete tumor remission | 60.0% | 73.9% | 85.0% |
Ranked by weight lost, surgery came first. Ranked by tumor remission, it came last.
Start with the denominators
That alone accounts for a large share of the apparent ordering. Before reaching for any explanation of why surgery underperformed, the first question is whether the difference exists at all, and 53 people split three ways cannot answer it.
Then the way people ended up in each group
Participants were not randomized. They arrived at their treatment after multidisciplinary assessment and shared decision-making, which is exactly right as clinical practice and fatal to the comparison.
So the most economical explanation for the inverse ordering is not that losing weight surgically harms tumor response. It is that the sickest patients were sent for the most aggressive intervention, and their tumors behaved accordingly.
This is the same problem we have documented repeatedly in observational comparisons of these drugs: treatment assignment carrying information about the patient. The general case is in when a hazard ratio is too good, and what a study can do to earn trust despite it is in how to trust an observational study. This study does none of those things, and does not claim to.
What to take from it anyway
One row holds up better than the others, though it still compares self-selected groups: weight regain between the first and second year was 14.3% in the lifestyle group against 55.6% and 66.7%, a difference the authors report as statistically significant.[1] It counts only the 29 women with complete two-year data, so each figure is a handful of people.
That fits everything else this register has documented about maintenance. The drug and the operation produce faster loss; keeping it requires something continuing. Two-thirds of the surgical patients with two-year data regaining in the second year is consistent with the wider evidence on weight regain after bariatric surgery, and the semaglutide figure fits a protocol that stopped the drug at least two months before any planned pregnancy.[1]
Frequently Asked Questions
References
- 1.Wei Y, Gong Y, Gong J, et al. Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study Journal of Obstetrics and Gynaecology. 2026. PMID: 42495930.
Compare the sellers
Related research
Cancer Risk in People Without Diabetes
A study in obese adults without diabetes found 41% lower incidence of obesity-associated cancers. The median follow-up was two years, far too short to establish that a drug prevented anything.
6 min read
GLP-1s and Cancer: The Randomized Answer
Randomized evidence finds little or no effect on obesity-related cancers: pancreatic somewhere between 9 fewer and 6 more per 10,000. The trials were not designed to look for cancer and had short follow-up.
6 min read
GLP-1s in People Being Treated for Cancer
Lower mortality and fewer hospitalizations than metformin, at a hazard ratio of 0.875. A second comparison against insulin produced a bigger number, and the bigger number is the less trustworthy one.
5 min read
GLP-1s and Cancer: What the Cohorts Actually Show
One study found breast cancer mortality 91% lower on GLP-1s than on insulin, and no difference at all against SGLT2 inhibitors. The comparison group produced the result. What is known, and how to read this kind of evidence.
7 min read
Are GLP-1s Longevity Drugs? What the Death and Outcome Data Show
GLP-1 drugs lower deaths from any cause by about 12% in people with heart disease, diabetes or kidney disease. No trial has tested them in healthy adults or measured lifespan. SELECT, FLOW, LEADER, dementia, cancer and muscle, in one place.
11 min read
The Line Is Drawn by Surgery
A meta-regression found study arms with greater average weight loss had higher rates of fatty liver disease resolving. The authors say plainly it cannot establish cause, and a handful of surgical arms are pulling the line.
6 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Gala
Moving between compounded and brand without changing seller
From $179/mo
Get started →Embody
A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies
From $79/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $99/mo
Get started →